Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to $5.5 million.

  • Iovance Biotherapeutics' Change in Accured Expenses fell 56.70% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year decrease of 16.89%. This contributed to the annual value of $8.6 million for FY2024, which is 56.62% down from last year.
  • Iovance Biotherapeutics' Change in Accured Expenses amounted to $5.5 million in Q3 2025, which was up 2,056.94% from -$281,000 recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Change in Accured Expenses peaked at $15.9 million during Q3 2023, and registered a low of -$23.0 million during Q1 2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was $4.1 million (2024), whereas its average is $3.3 million.
  • Data for Iovance Biotherapeutics' Change in Accured Expenses shows a peak YoY increase of 324.05% (in 2024) and a maximum YoY decrease of 154.20% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Change in Accured Expenses (Quarterly) stood at $9.4 million in 2023, then tumbled by 56.58% to $4.1 million in 2024, then plummeted by 56.70% to $5.5 million in 2025.
  • Its Change in Accured Expenses stands at $5.5 million for Q3 2025, versus -$281,000 for Q2 2025 and $2.2 million for Q1 2025.